Guidance in the Red / Amber List serves ONLY to define where clinical and prescribing responsibility for the listed medicines should lie in terms of governance and safety.
- Inclusion in this list does NOT imply the medicine has been accepted for use via Managed Entry, does NOT imply endorsement of use, and does NOT take account of the cost implications of use of a particular medicine.
- Prescribers should use this list in conjunction with guidance on the Managed entry process for medicines, and the NI formulary which includes information on current cost effective choices.
- As far as possible, new specialist medicines are added to the list at the point when they are granted a UK product licence. In some instances this may be prior to the medicine being launched.
The table below lists specialist medicines. Users should search by generic name where possible. Brand names listed are not exhaustive.
Show All Entries A-B C-D E-J K-M N-R S-Z
Approved Name | Example Trade Names | Context | Status | Guidance | New Entry |
---|---|---|---|---|---|
Sacituzumab govitecan | Trodelvy | Red | |||
Sapropterin | Kuvan | Red | |||
Saquinavir | Invirase | Red | |||
Sarilumab | Kevzara | Red | |||
Sebelipase alfa | Kanuma | Red | |||
Secukinumab | Cosentyx | Red | |||
Selexipag | Uptravi | Red | |||
Selinexor | Nexpovio | Red | |||
Selpercatinib | Retsevmo | Red | |||
Selumetinib | Koselugo | Red | |||
Setmelanotide | Imcivree | Red | |||
Sildenafil | Revatio | Pulmonary arterial hypertension | Amber | Sildenafil Shared Care Guideline | |
Sildenafil | Viagra | Erectile dysfunction - severe distress category only | Red | ||
Siltuximab | Sylvant | Red | |||
Simeprevir | Olysio | Red | |||
Siponimod | Mayzent | Red | |||
Sirolimus | Rapamune | Amber | Sirolimus Shared Care Guideline | ||
Sodium clodronate | Bonefos | IV only; hypercalcaemia of malignancy | Red | ||
Sodium oxybate | Xyrem | Red | |||
Sodium phenylbutyrate | Ammonaps | Amber | GP Information Sheet | ||
Sofosbuvir | Solvadi | Red | |||
Sofosbuvir + ledipasvir | Harvoni | Red | |||
Sofosbuvir + velpatasvir | Epclusa | Red | |||
Sofosbuvir + voxilaprevir + velpatasvir | Vosevi | Red | |||
Somapacitan | Sogroya | Amber | Shared Care Guideline In Development | ||
Somatrogon | Ngenla | Amber | Shared Care Guideline In Development | ||
Somatropin | Genotropin, Norditropin, Humatrope, Saizen, Zomacton | Amber | Somatropin Shared Care Guideline | ||
Sonidegib | Odomzo | Red | |||
Sorafenib | Nexavar | Red | |||
Sotorasib | Lumykras | Red | |||
Stiripentol | Diacomit | Amber | GP Information sheet | ||
Sulfasalazine | Salazopyrin | Amber | Sulfasalazine Shared Care Guideline | ||
Sunitinib | Sutent | Red | |||
Tacrolimus | Prograf | Immunosuppressant post transplantation | Amber | Tacrolimus Post Transplant Shared Care Guideline | |
Tacrolimus | Prograf | Non-transplant indications | Amber | Tacrolimus Non-Transplant Shared Care Guideline | |
Tadalafil | Adcirca | Pulmonary arterial hypertension | Amber | Tadalafil Shared Care Guideline | |
Tadalafil | Cialis | Erectile dysfunction - severe distress category only | Red | ||
Tafamidis | Vyndaqel | Red | |||
Tafasitamab | Minjuvi | Red | |||
Talazoparib | Talzenna | Red | |||
Talimogene laherparepvec | Imlygic | Red | |||
Tebentafusp | Kimmtrak | Red | |||
Teclistamab | Tecvayli | Red | |||
Tedizolid | Sivextro | Red | |||
Teduglutide | Revestive | Red | |||
Tegafur with gimeracil and oteracil | Teysuno | Red | |||
Tegafur with uracil | Uftoral | Red | |||
Teicoplanin | Targocid | Red | |||
Telaprevir | Incivo | Red | |||
Telbivudine | Sebivo | Red | |||
Telotristat | Xermelo | Red | |||
Temozolomide | Temodal | Red | |||
Tenofovir | Viread | Red | |||
Tenofovir, alafenamide, elvitegravir, cobicistat + emtricitabine | Genvoya | Red | |||
Tepotinib | Tepmetko | Red | |||
Teriflunomide | Aubagio | Red | |||
Teriparatide | Forsteo | Red | |||
Testosterone | Amber | Testosterone Shared Care Guideline | |||
Tezacaftor with Ivacaftor | Symkevi | Red | |||
Tezepelumab | Tezspire | Red | |||
Thalidomide | Pharmion | Red | |||
Thioridazine | Red | ||||
Tildrakizumab | Ilumetri | Red | |||
Tinzaparin Sodium | Innohep | Amber | No Shared Care Guideline Required (Click for info) | ||
Tioguanine | Lanvis | Red | |||
Tipiracil + trifluridine | Lonsurf | Red | |||
Tipranavir | Aptivus | Red | |||
Tivozanib | Fotivda | Red | |||
Tobramycin | Tobi, Nebcin | IV or nebulised | Red | ||
Tocilizumab | RoActemra | Red | |||
Tofacitinib | Xeljanz | Red | |||
Tolcapone | Tasmar | Amber | Tolcapone Shared Care Guideline | ||
Tolvaptan | Samsca, Jinarc | Red | |||
Topotecan | Hycamtin | Red | |||
Total Parenteral Nutrition (TPN Solutions) | Red | ||||
Tralokinumab | Adtralza | Red | |||
Trametinib | Mekinist | Red | |||
Tranylcypromine | Amber | No Shared Care Guideline Required (Click for info) | |||
Trastuzumab | Herceptin, including Herceptin SC | Red | |||
Trastuzumab deruxtecan | Enhertu | Red | |||
Trastuzumab emtansine | Kadcyla | Red | |||
Treosulfan | Red | ||||
Treprostinil | Red | ||||
Tretinoin | Vesanoid | Red | |||
Trientine | Amber | No Shared Care Guideline Required (Click for info) | |||
Triptorelin | Decapeptyl, Gonapeptyl, Salvacyl | When used for treatment of infertility | Red | ||
Tucatinib | Tukysa | Red | |||
Turoctocog alfa | NovoEight | Red | |||
Ulipristal (as Esmya) | Uterine fibroids | Amber | Shared Care Guideline in development | ||
Unlicensed Cannabis Based Products for Medicinal Use (CBPM) Licensed CBPMs are considered separately under their Brand Names. | > A cannabis-based medicine must meet the definition of the 2018 No 173 The Misuse of Drugs (Amendment No 2) Regulations (Northern Ireland). > If it is not a licensed medicine (UK) the CBPM should meet the definition of a special medicinal product and be for use in accordance with a prescription or direction of a specialist medical practitioner | Red | |||
Upadacitinib | Rinvoq | Red | |||
Ustekinumab | Stelara | Red | |||
Valganciclovir | Valcyte | Red | |||
Vandetanib | Caprelsa | Red | |||
Vardenafil | Levitra | Erectile dysfunction - severe distress category only | Red | ||
Vedolizumab | Entyvio | Red | |||
Velaglucerase alfa | VPRIV | Red | |||
Vemurafenib | Zelboraf | Red | |||
Venetoclax | Venclyxto | Red | |||
Venlafaxine | Efexor | Only considered specialist medicine (Amber category) at doses greater than 300mg daily | Amber | No Shared Care Guideline Required (Click for info) | |
Vestronidase | Mepsevii | Red | |||
Vinorelbine | Navelbine | Red | |||
Vismodegib | Erivedge | Red | |||
Volanesorsen | Waylivra | Red | |||
Vonicog alfa | Veyvondi | Red | |||
Voriconazole | Vfend | Red | |||
Warfarin | Amber sub-group | Local Arrangements For Shared Care May Apply | |||
Zanubrutinib | Brukinsa | Red | |||
Zidovudine | Retrovir | Red | |||
Zidovudine with lamivudine | Combivir | Red | |||
Zoledronic acid | Aclasta, Zometa | Red |